Autoimmune Hepatitis Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Kezar Life Sciences, Novartis, MorphoSys, Jiangsu HengRui Medicine Co., Ltd., TaiwanJ Pharma

DelveInsight's "Autoimmune Hepatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Autoimmune Hepatitis, historical and forecasted epidemiology as well as the Autoimmune Hepatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Autoimmune Hepatitis, offering comprehensive insights into the Autoimmune Hepatitis revenue trends, prevalence, and treatment landscape. The report delves into key Autoimmune Hepatitis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Autoimmune Hepatitis therapies. Additionally, we cover the landscape of Autoimmune Hepatitis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Autoimmune Hepatitis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Autoimmune Hepatitis space.

To Know in detail about the Autoimmune Hepatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Autoimmune Hepatitis Market Forecast
https://www.delveinsight.com/sample-request/autoimmune-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Autoimmune Hepatitis Market Report:
• The Autoimmune Hepatitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In October 2024, Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for immune-mediated diseases, has provided key clinical development updates. The Independent Data Monitoring Committee (IDMC) overseeing the PORTOLA Phase 2a trial of zetomipzomib in patients with autoimmune hepatitis (AIH) has recommended the trial continue without modifications following its third scheduled review. The IDMC assessed safety data from all enrolled patients, including those who completed the blinded treatment phase and transitioned into the open-label extension, which includes an additional 24 weeks of treatment.
• In November 2024, After patient fatalities in a lupus trial that resulted in the program's termination, Kezar Life Sciences announced a partial clinical hold on its autoimmune candidate, zetomipzomib. This hold will prevent four participants from continuing treatment in the open-label segment of the ongoing trial, although the trial will proceed as scheduled. This action follows an earlier clinical hold imposed by the FDA in October 2024 for zetomipzomib in lupus and now extends to a Phase 2 trial in autoimmune hepatitis.
• Key Autoimmune Hepatitis Companies: Kezar Life Sciences, Novartis/MorphoSys, Jiangsu HengRui Medicine Co., Ltd., TaiwanJ Pharmaceuticals, Novartis, and others
• Key Autoimmune Hepatitis Therapies: Zetomipzomib (KZR-616), Ianalumab (VAY736), HR19042 Capsules, JKB-122, VAY736, and others
• The Autoimmune Hepatitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Autoimmune Hepatitis pipeline products will significantly revolutionize the Autoimmune Hepatitis market dynamics.
• The prevalence of Autoimmune Hepatitis (AIH) in the United States is estimated to be around 31.2 cases per 100,000 individuals.
• The prevalence of Autoimmune Hepatitis (AIH) in the United States was found to be higher in females, at 45.0 per 100,000, compared to 13.9 per 100,000 in males.
• AIH prevalence was found to be highest in the 7th decade of life and decreased thereafter. Specifically, the prevalence in the elderly (over 65 years) was 59.0 per 100,000, compared to 28.5 per 100,000 in adults (18-65 years) and 2.4 per 100,000 in children (under 18 years) in the United States.
• The prevalence of AIH in Germany was found to be approximately 23 per 100,000 inhabitants.
• The prevalence of AIH in Japan was reported to be around 23.4 per 100,000 individuals.

Autoimmune Hepatitis Overview
Autoimmune Hepatitis (AIH) is a chronic liver disease in which the body's immune system mistakenly attacks the liver cells, causing inflammation and potential liver damage. It is characterized by elevated liver enzymes, the presence of autoantibodies, and histological liver damage. The exact cause is unknown, but genetic and environmental factors, such as infections or certain medications, may trigger the immune response. AIH can lead to cirrhosis and liver failure if left untreated, but with proper treatment, such as immunosuppressive therapy, the disease can often be managed effectively.

Get a Free sample for the Autoimmune Hepatitis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/autoimmune-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Autoimmune Hepatitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Autoimmune Hepatitis Epidemiology Segmentation:
The Autoimmune Hepatitis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Autoimmune Hepatitis
• Prevalent Cases of Autoimmune Hepatitis by severity
• Gender-specific Prevalence of Autoimmune Hepatitis
• Diagnosed Cases of Episodic and Chronic Autoimmune Hepatitis

Download the report to understand which factors are driving Autoimmune Hepatitis epidemiology trends @ Autoimmune Hepatitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/autoimmune-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Autoimmune Hepatitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autoimmune Hepatitis market or expected to get launched during the study period. The analysis covers Autoimmune Hepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Autoimmune Hepatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Autoimmune Hepatitis Therapies and Key Companies
• Zetomipzomib (KZR-616): Kezar Life Sciences
• Ianalumab (VAY736): Novartis/MorphoSys
• HR19042 Capsules: Jiangsu HengRui Medicine Co., Ltd.
• JKB-122: TaiwanJ Pharmaceuticals
• VAY736: Novartis

Discover more about therapies set to grab major Autoimmune Hepatitis market share @ Autoimmune Hepatitis Treatment Landscape
https://www.delveinsight.com/sample-request/autoimmune-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Autoimmune Hepatitis Market Drivers
• Increasing Prevalence
• Advancements in Treatment
• Improved Diagnostic Tools
• Expanding Healthcare Access
• Research and Development Investments

Autoimmune Hepatitis Market Barriers
• High Treatment Costs
• Unmet Medical Needs
• Adverse Side Effects
• Lack of Awareness
• Regulatory Challenges

Scope of the Autoimmune Hepatitis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Autoimmune Hepatitis Companies: Kezar Life Sciences, Novartis/MorphoSys, Jiangsu HengRui Medicine Co., Ltd., TaiwanJ Pharmaceuticals, Novartis, and others
• Key Autoimmune Hepatitis Therapies: Zetomipzomib (KZR-616), Ianalumab (VAY736), HR19042 Capsules, JKB-122, VAY736, and others
• Autoimmune Hepatitis Therapeutic Assessment: Autoimmune Hepatitis current marketed and Autoimmune Hepatitis emerging therapies
• Autoimmune Hepatitis Market Dynamics: Autoimmune Hepatitis market drivers and Autoimmune Hepatitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Autoimmune Hepatitis Unmet Needs, KOL's views, Analyst's views, Autoimmune Hepatitis Market Access and Reimbursement

To know more about Autoimmune Hepatitis companies working in the treatment market, visit @ Autoimmune Hepatitis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/autoimmune-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Autoimmune Hepatitis Market Report Introduction
2. Executive Summary for Autoimmune Hepatitis
3. SWOT analysis of Autoimmune Hepatitis
4. Autoimmune Hepatitis Patient Share (%) Overview at a Glance
5. Autoimmune Hepatitis Market Overview at a Glance
6. Autoimmune Hepatitis Disease Background and Overview
7. Autoimmune Hepatitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Autoimmune Hepatitis
9. Autoimmune Hepatitis Current Treatment and Medical Practices
10. Autoimmune Hepatitis Unmet Needs
11. Autoimmune Hepatitis Emerging Therapies
12. Autoimmune Hepatitis Market Outlook
13. Country-Wise Autoimmune Hepatitis Market Analysis (2019-2032)
14. Autoimmune Hepatitis Market Access and Reimbursement of Therapies
15. Autoimmune Hepatitis Market Drivers
16. Autoimmune Hepatitis Market Barriers
17. Autoimmune Hepatitis Appendix
18. Autoimmune Hepatitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Autoimmune Hepatitis Pipeline https://www.delveinsight.com/report-store/autoimmune-hepatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Autoimmune Hepatitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Autoimmune Hepatitis market. A detailed picture of the Autoimmune Hepatitis pipeline landscape is provided, which includes the disease overview and Autoimmune Hepatitis treatment guidelines.

Autoimmune Hepatitis Epidemiology https://www.delveinsight.com/report-store/autoimmune-hepatitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Autoimmune Hepatitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Autoimmune Hepatitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market
• Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.